Introduction
Cardiac resynchronization therapy (CRT) is beneficial in NYHA II-IV heart failure (HF) with reduced ejection fraction (HFrEF) and electrical dyssynchrony. 1 However, CRT may be underutilized. 2 The Institutes of Medicine has identified implementation of safe and effective interventions into broad clinical practice as a major area needing improvement. 3 We have previously described that as many as 30% of HFrEF patients may have indication for CRT, and that wide QRS and LBBB are associated with increased mortality consistently across varying demographics and independently of extensive baseline covariates. 4 -7 In recent years, indications have expanded to include NYHA II HF patients. Concurrently, the selection criteria for CRT have also been modified to identify patients more likely to respond to CRT, with wider QRS and LBBB 8 which may have counterbalanced the expected rise in CRT utilization. A QRS width of 120-149 ms without LBBB morphology may, however, still be considered (IIb) for CRT according to the 2013 European Heart Rhythm Association (EHRA) guidelines. 8, 9 The reasons for CRT underutilization may include unawareness of indications, variable acceptance, organizational aspects, or cost concerns affecting access, and concerns over complications and non-response in real-life patients. In order to focus CRT educational, implementation, and accessibility efforts, there is a need for better knowledge of factors associated with inappropriate CRT non-use. Therefore, we assessed in NYHA II-IV HFrEF: the prevalence of CRT indication and CRT use, and in patients with CRT indication, independent associations between demographic, organizational, socio-economic, and clinical variables and CRT non-use.
Methods

Study population and independent variables
The Swedish Heart Failure Registry (SwedeHF) has been previously described 10 and provided the study population and baseline clinical characteristics and medications. Inclusion criteria in SwedeHF are clinician-judged HF. Approximately 80 variables are recorded at discharge from hospital or outpatient visits at cardiology, internal medicine, and primary care clinics. The protocol, registration form, and annual reports are available at www.SwedeHF.se.
Patients were included in this study if the index date was between 11 May 2000 (start of the Registry) and 31 December 2012 (date of last data for this study). The index date was defined as the date of outpatient visit or hospital discharge; patients who died during the index hospitalization were excluded. Additional inclusion criteria were those where a CRT indication may be present, i.e. NYHA II-IV (patients with NYHA I were excluded even if a CRT device was present) and reduced EF (defined as ≤39%). In SwedeHF, EF is categorized as <30, 30-39, 40-49, and ≥50%. CRT is indicated with EF ≤35%. In Sweden, EF is overwhelmingly reported in 5-10% increments. Therefore, for EF 30-39%, we assumed that a vast majority had a true EF of 30-35% and that few had 36-39%, but a consistency analysis requiring EF ≤30% was also performed. Exclusion criteria are shown in the flow chart in Figure 1 , and included inability to interpret QRS and LBBB, such as in the presence of a potentially Table S1 ) for encounters as inpatients and as outpatients at specialty (but not primary care) clinics. The positive predictive value for most ICD-10 diagnoses in Sweden is 85-95%. 11 Co-morbidities present at baseline were defined by corresponding ICD-10 codes in any position between 1 January 1997, when use of ICD-10 codes began in Sweden, and up to and including the index date (except malignancy, musculoskeletal, and psychiatric disorders, counted only if the corresponding ICD-10 code was present, i.e. a healthcare encounter for this diagnosis had occurred, in the last 3 years prior to the index date). Finally, Statistics Sweden (www.scb.se) maintains demographic and socio-economic data on all Swedish citizens and provided additional baseline data, including level of education and income.
Dependent variables
The dependent variable of interest was CRT non-use despite the presence of a CRT indication. CRT use was obtained from SwedeHF and categorized as CRT present (and indication assumed); CRT absent but indication present; and CRT appropriately absent due to absence of indication. In a separate analysis of all patients with CRT (with QRS not interpretable and regardless of EF, NYHA class, and rhythm, thus a greater sample than those included for the main analysis), we assessed what proportion no longer met CRT criteria. This was based on NYHA class, EF, and rhythm, since QRS is paced and not interpretable.
Numerous guidelines for CRT have been published in recent years. For this analysis, we needed a reasonable and consistent definition of CRT indication roughly reflecting the overall knowledge during the study period and not being too strict or too generous. CRT indication was defined as the most reasonable or accepted, i.e. class I or IIa (but not IIb) indications in the 2013 EHRA guidelines: 8 EF ≤35%, NYHA II-IV, and QRS ≥120 ms, where NYHA II also required sinus rhythm and QRS 120-149 ms also required LBBB ( Table 1 , scenario 1).
We assessed the extent and predictors of CRT non-use using these criteria.
For completeness, we also assessed CRT use in several consistency analyses ( Table 1) : scenario 2, liberal: according to EHRA I-IIa but also IIb: QRS 120-149 ms even in the absence of LBBB morphology; scenario 3, to rule out that some in the EF 30-39% group had EF 36-39% and were thus not eligible for CRT, we required EF ≤30% for CRT, and defined EF 30-39% as absent CRT indication, and to rule out that some NYHA IV were not ambulatory, we required NYHA II-III for CRT, and defined NYHA IV as absent CRT indication (even though all patients were recorded at discharge alive or as outpatients); scenario 4, excluding all patients with a duration <6 months, to allow that some of these patients may be new diagnoses where up-titration of drugs and improvement of EF and NYHA class or implantation of CRT after index were possible; and scenario 5, excluding all patients before 2010, to allow that evidence for current CRT recommendations did not emerge until then.
Statistics
Baseline characteristics for the three groups were tabulated and compared by 2 tests (all variables were categorical or categorized) ( Table 2 ). All subsequent analyses were performed only in patients with CRT indication comparing CRT use vs. non-use.
To determine associations between demographic, organizational, socio-economic, and clinical characteristics and CRT non-use, we used generalized estimating equation (GEE) models with a Poisson distribution and a log link with a robust variance (20) yielding uniand multivariable (adjusted) risk ratios (RRs) for each characteristic in association with CRT non-use. The 37 variables included in the model are numbered in Table 2 . The dfbetas were used to detect outliers, and none was detected. Because predictors of CRT non-use are presently unknown, because they may reasonably be assumed potentially to consist of demographic, organizational, socio-economic, and clinical factors, and because the sample size was sufficiently large, we included all variables that we estimated may directly or indirectly affect CRT use.
Some baseline independent variables (but no CRT criteria or CRT use) had missing data. Table 2 specifies percentage missing for each variable. In the multivariable GEE models, to avoid bias and confounding due to variables not missing completely at random, multiple imputation (n = 10) was performed for all variables in the models with missing data, using predictive mean matching with the 37 variables numbered in Table 2 . Imputation corrections to the resulting standard errors were performed. Because NT-proBNP was not used in the earlier years of our study and thus is missing in a considerable proportion of patients, we also performed an additional consistency analysis of associations with non-use, excluding NT-proBNP from the imputation and GEE models.
Statistical analyses were performed using R version 3.1.3 (R Foundation for Statistical Computing, Vienna, Austria). The level of significance was 5% and all P-values and confidence intervals (CIs) were two-sided.
Ethics
Establishment of the SwedeHF Registry and this analysis with linking of the above registries was approved by a multisite ethics committee. Individual patient consent was not required, but patients were informed of entry into national registries and allowed to opt out. 
Results
Between 11 May 2000 and 31 December 2012, there were 12 807 patients (mean age 71 ± 12 years, 28% female) who met study eligibility criteria ( Figure 1 ; Table 2 ).
Patient characteristics and cardiac resynchronization therapy utilization
Of 12 807 patients, 841 (7%) had CRT. According to class I-IIa recommendation (main analysis), 3094 patients (24%) had indication for CRT but were not treated, and the remainder (8872; 69%) had no indication. Thus 841 + 3094 = 3935 (31% of total) had indication for CRT and, of those, only 841 (21%) were treated and 3094 (79%) were untreated despite indication. Table 1 shows eligibility according to the different consistency analyses. Patient characteristics for the main analysis in the overall population (three groups) are shown in Table 2 and were considerably different. Patients with CRT non-use were older, more commonly women, treated at small-town and non-university hospitals and more often both cared for in (at the index presentation) and referred for follow-up to non-cardiology clinics. However, they were more often planned for follow-up in HF nurse clinics. They more often were living alone and had some form of psychiatric disease or diagnosis.
Among patients with CRT (841 in the main analysis plus an additional 294 excluded from the main analysis, making a total of 1135), 227 (20%) no longer met at least one criterion for CRT: 144 (13%) had EF ≥40%; 55 (4.8%) had sinus rhythm and NYHA I; and 57 (5.0%) had chronic AF and NYHA I-II. Table S2 in the Supplementary material online shows comprehensive uni-and multivariable relative risk of CRT non-use among patients with CRT indication, for each of the 37 patient characteristics. In univariable analysis, characteristics associated with non-use were demographic or organizational factors such as HF duration <6 months, age >75 years, female sex, living alone, smoking, alcoholism, receiving care at a small town non-university centre, an outpatient setting, and internal medicine or geriatrics (as opposed to cardiology) settings; clinical factors associated with milder HF, such as shorter duration, NYHA II, EF 30-39% (vs. <30%), and higher blood pressure (but not NT-proBNP), and absence of co-morbidities such as history of myocardial infarction, atrial fibrillation/flutter, diabetes, and musculoskeletal disorders (but not cancer which was neutral, and psychiatric diagnosis, which was associated with increased risk of CRT non-use), less use of HF medications, and socio-economic factors such as lower education and income.
Associations with cardiac resynchronization therapy non-use
In multivariable analyses, many of these remained significant, including HF duration <6 months (RR 1.21, 95% CI 1.17-1.24); planned follow-up to non-cardiologists (RR 1.14, 95% CI 1.09-1.18); age >75 years (RR 1.13, 95% CI 1.09-1.18); non-cardiology care (RR, 1.10 95% CI 1.07-1.14); small-town non-university centre (RR 1.08, 1.05-1.12); female sex (RR 1.07, 95% CI 1.03-1.10) (all P < 0.05); as well as living alone; psychiatric diagnosis; smoking; and non-use of HF drugs. Education and income were no longer significant and, among clinical variables, only AF remained significant with a clinically meaningful negative association with CRT non-use (RR 0.82, 95% CI 0.79-0.86, P < 0.001) (i.e. presence of AF was associated with lower risk of CRT non-use). For simplicity and completeness, Figure 2 presents adjusted risk ratios for CRT non-use in descending order of relative risk for those that were ( Figure 2A ) and were not ( Figure 2B ) independently statistically significantly associated with CRT non-use, and colour coded according to the type of variable (red, demographic/organizational; blue, clinical/co-morbidity; green, HF medication use; and black, socio-economic). In the consistency analysis without NT-proBNP, associations with CRT non-use were similar.
Discussion
In this large analysis from the nationwide Swedish HF Registry we show that CRT was overall underutilized and CRT non-use was independently associated primarily with demographic and organizational but not clinical factors. 15 Thus, in order to improve CRT utilization, it is critical to assess factors that may be associated with inappropriate CRT non-use.
Cardiac resynchronization therapy underutilization
Associations with cardiac resynchronization therapy non-utilization
Organizational factors
An important factor associated with CRT non-use was shorter duration of HF, which is appropriate in that drug up-titration and EF Data are n (%); percentages sum up to 100% horizontally (or near 100%, due to rounding). P-value is overall for three groups using 2 (all variables categorical or categorized). BP, blood pressure; CABG, coronary artery bypass graft surgery; CRT, cardiac resynchronization therapy; HF, heart failure; MRA, mineralocorticoid receptor antagonist; TIA, transient ischaemic attack. a Numbers indicate the 37 variables included in multivariable GEE models to predict CRT non-use, in multivariable Cox models to predict outcomes, and in multiple imputations for missing data. Variables without numbers are shown for descriptive purposes.
and NYHA improvement may still be possible and CRT can reasonably be deferred. However, in a non-cardiology specialist setting, drug optimization may also be delayed or neglected, and, indeed, non-cardiology care, non-cardiology follow-up, and non-use of HF medications were also associated with CRT non-use. Sweden has seven medical universities, located primarily in larger cities or towns. Of ∼70 hospitals in total in Sweden, >65 reported to SwedeHF during the study period, but a majority of hospitals do not have cardiology specialist wards or outpatient clinics. Even at referral centres, patients are generally seen only at critical points in the course of their disease, and routine care is provided by internal medicine or primary care clinics. This is consistent with our findings that non-cardiology care and follow-up as well as smaller town and non-university settings were important factors associated with CRT non-use. In fact, one might argue that some untreated patients would receive CRT during follow-up, but CRT non-users received less cardiology follow-up referrals, indicating that HF optimization was not planned to a greater extent in CRT non-users. We have previously reported that cardiology subspecialty was the only significant predictor of physicians' awareness of indications for CRT therapy in a nationwide Swedish physician survey. wide set of physician specialties were aware of the indications for CRT, with the highest proportions in cardiologists (95%) and the lowest in general practitioners (6%). Taken together, these data suggest that both broad educational efforts and improved access to cardiology specialist care are critical for improved utilization of CRT.
Demographic factors
Older and female patients are under-represented in clinical trials and underserved by evidence-based HF therapy in general, 17 and indeed were at higher risk for CRT non-use in our study. While this was not unexpected, it is worth underscoring, because there is no evidence that CRT benefits are less in these patients. Indeed, in a large US registry, CRT was associated with improved survival irrespective of age, including patients >80 years old. 18 Furthermore, recent studies show potentially greater CRT benefit in women than in men 19 -21 and potentially at a narrower QRS width. 20 We cannot rule out that the elderly or women were more reluctant to accept CRT, and, indeed, women may have lower enthusiasm for technical interventions and more concerns for complications than men. 22 This is also consistent with previous revascularization but not ischaemic heart disease itself (where patients derive less reverse remodelling but similar clinical benefits) being associated with CRT use, at least partly suggesting that patient willingness to undergo CRT implantation may parallel willingness to undergo other interventions. However, this highlights even more the need for not only clinician but also patient education.
Clinical (heart failure and co-morbidity) characteristics
Several characteristics indicating milder HF (by, for example, EF, NYHA class, anaemia, or NT-proBNP) were associated with CRT non-use in univariable but not multivariable analysis, suggesting that after considering other factors, CRT use is equally accessible also to patients with milder HF including NYHA II. The benefits of CRT are as great in NYHA class II. 23 In contrast, higher blood pressure and better renal function were associated with non-use, suggesting that those with or approaching end-stage HF with end-organ dysfunction may be prioritized for CRT, conceivably too late. Notably, AF was associated with lower risk of CRT non-use. Given the greater strength of evidence and guideline recommendations down to NYHA II for sinus rhythm, 8 this was unexpected. Our analyses were adjusted for NYHA class but may be confounded by greater access to electrophysiology expertise for patients with AF. Nevertheless, it seems that AF is at least not a deterrent for CRT in Sweden. Similarly, history of PCI and/or coronary artery bypass graft was associated with lower risk of CRT non-use, again suggesting that cardiovascular co-morbidities may be associated with greater access to cardiology and HF expertise.
Socio-economic factors
Socio-economic characteristics are known to affect therapy and outcomes in HF and cardiovascular disease in general, 17 but whether this applies specifically to CRT utilization is unknown. Smoking and a psychiatric diagnosis were associated with CRT non-use, suggesting that some unknown patient or clinician perceptions, biases, or judgements may affect CRT recommendations or acceptance. In contrast, cancer, lung disease, musculoskeletal disease, anaemia, or prior stroke/transient ischaemic attack were not associated with CRT non-use, suggesting that prognostically adverse co-morbidities may not affect decisions to recommend or accept CRT. Living alone, but not having children, was associated with CRT non-use, suggesting that a spouse may advocate for and contribute to patient and clinician acceptance, whereas children may not push for or against such decisions, which may be quite different from other cultural settings, where families and/or children may have greater influence. While access to healthcare is universal and government funded in Sweden, socio-economic factors may nevertheless affect patient awareness and the seeking of and pushing for care and referrals. Therefore, it was reassuring that education or income were not associated with CRT non-use. We cannot rule out that in countries with different health systems, these factors may nevertheless adversely . 
Actions to improve appropriate cardiac resynchronization therapy utilization
The experience from systematic efforts such as the IMPROVE HF study indicates that educational activities directed at physicians at cardiology outpatient clinics enhance HF therapy utilization including CRT. 24 Other initiatives such as annual reports from Patient Registries that provide benchmarking possibilities may also improve therapy including CRT. The results of the first European CRT survey indicated both over-and underuse of CRT according to the available guidelines at the time. 25 The second CRT survey is ongoing in >40 European countries and provides national and international benchmarking possibilities for indications and quality of care in conjunction with CRT device implantation and follow-up.
26
Limitations
We cannot rule out that some patients with CRT may not have met criteria at the time of implant. However, we needed to include patients with CRT as the comparator in the GEE models, and therefore we needed to assume that criteria had been met. Our analysis is a snap-shot of CRT use and we cannot rule out that patients without CRT may have received CRT during follow-up or improved such that CRT may no longer be indicated. However, CRT non-users were less frequently referred for cardiology follow-up, suggesting that the clinician may not have considered CRT or at least did not plan CRT to any significant extent. Given that a majority of patients with a CRT indication were not treated (79%), it is unlikely that a significant proportion would receive CRT in the foreseeable future. The classification of covariates into red, demographic/organizational; blue, clinical/co-morbidity; green, HF medication use; and black, socio-economic was for simplification, but certainly several variables have elements of several categories and the distinctions made may be somewhat arbitrary. Patients were enrolled both before and after the publication of different trials and guidelines for CRT. To define CRT indication, we therefore needed the criteria most reasonably reflecting the general knowledge base during the study period. Therefore, although we recognize that this is arbitrary, the main analysis defined CRT indication as EHRA class I-IIa recommendations, but with consistency analyses with both more liberal and more strict criteria or definitions, a majority of patients with a CRT indication were still untreated. Associations between patient characteristics and CRT non-use were assessed only according to the I-IIa definition, but it is unlikely that characteristics associated with CRT non-use would be dramatically different in different scenarios. Although all variables were categorized, relative risks were not necessarily comparable since some variables had >2 levels. While we assessed the relative risk for each potential characteristic associated with CRT non-use, we could not quantify their individual independent roles. This would have required population-attributable risk analyses which were not feasible due to the large number of characteristics and relatively weak individual contributions to CRT non-use.
Conclusions
In this population-wide HF registry, CRT was underutilized. Non-use was associated primarily with demographic and organizational, but not clinical factors. This calls for programmes to raise awareness of CRT indications and improve access and referrals to cardiology specialists.
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